We don't foresee any impact on pharma companies' moats or valuations.
Astra’s vaccine looks potentially easier to transport with only mild temperature requirements as compared with the other vaccines.
After reporting strong final data, we expect emergency authorization of Pfizer and BioNTech's vaccine by early December.
With the vaccine’s efficacy over 90% and no major safety issues observed, we believe Pfizer and BioNTech's vaccine is set up for emergency use in late 2020, followed by full approval in 2021 pending supportive final data.
Although the outcome of the U.S. election is still uncertain, we do not expect the results to affect our valuations or moat ratings in the biopharma industry.
We continue to see the company as undervalued and maintain our narrow moat rating.
The wide-moat drug manufacturer plans to release key data on COVID-19 vaccine shortly.
We continue to view Merck as undervalued, with the market not fully appreciating the firm’s strong immuno-oncology platform.
The wide-moat drug manufacture plans to acquire Asklepios BioPharmaceuticals.
The wide-moat company reported above our expectations, and we expect to slightly increase our fair value estimate.
And four companies we like right now.
We expect a coronavirus vaccine to be released within the next six months.
Despite the hold on vaccine development, we are not changing our fair value estimate or moat rating for the company.
This acquisition reinforces the intangible assets supporting J&J's wide moat, and we plan to raise our fair value estimate for Momenta.
We don’t expect any major changes to our AbbVie fair value estimate for the narrow-moat company.
Moats and returns on invested capital look stable for companies with a solid list of pipeline drugs.
We don’t expect any significant fair value estimate changes for this wide-moat company based on the minor outperformance.
We don’t expect these actions by President Trump to significantly affect our fair value estimates or moat ratings due to limited details, challenging implementation, and only minor impacts.
The company's drug group helps offset COVID-19 pressure on device sales.
And what we expect to see moving forward.
Changes to U.S. healthcare policy no longer a major fear.
While the costs will deplete capital, we don’t expect the settlement to create a major drag on the firm’s wide moat.
The wide-moat drugmaker's growth prospects are improving.
Strong cash flows support drug development and a dividend that yields above 4%.
Our valuation and moat rating aren't affected by this company's decision.
Necessity means dividends are very secure for drugmakers.
We continue to view the wide-moat company as fairly valued, with the market appropriately appreciating the heavy patent losses over the next five years.
We continue to view this wide-moat stock as undervalued and maintain our fair value estimate.
The wide-moat firm faces market headwinds, but we anticipate its outlook will reverse in 2021.
We expect J&J to lead the charge in developing a coronavirus vaccine and view the stock as slightly overvalued.
Moats, valuations, and dividends look attractive in the market pullback.
Drug manufacturers are the most undervalued industry in the sector.
Fears of a progressive president and changes to the healthcare system have faded.
Our base case calls for a strong economic rebound in 2021 following a recession in 2020.
Biden's nomination would reduce the likelihood of significant drug pricing policy changes, which is in line with our expectations.
We see some opportunity for investment, especially in Merck.
An ESG frame helps us bring a better look at valuation within the healthcare sector.
We plan to maintain our fair value estimate for the wide-moat firm, which offered solid 2020 guidance.
We have raised our fair value estimate based on an improving outlook.
Results for the wide-moat firm were slightly below expectations due to marketing expenditures.
We expect the strong 2020 guidance to support a slight increase to our fair value estimate, but we still don’t expect the stock to look undervalued.
We don't expect a major overhaul of the U.S. healthcare system.
The narrow-moat firm is undervalued and well-positioned with its dividend.
Recent results from some of the most undervalued large drugmakers we cover.
We don't see any major impact to our fair value estimate based on the quarter's outperformance.
We see opportunities in providers, managed care, drugs, and biotech.
Check out these pharmaceutical stocks for both capital appreciation and dividend yield.
The $572 million payment amount for Johnson & Johnson is lower than expected, and the wide-moat firm plans to appeal the case.
The divestment of the generics business should strengthen Pfizer's competitive positioning.
Sector director Damien Conover shares his key takeaways from Johnson & Johnson, Novartis, Glaxo, and Bristol Myers Squibb's reports.